Sugi Predict

Sugi Predict / Compounds / SCHEMBL354556

SCHEMBL354556

SCHEMBL354556

O=C(O)C(F)(F)c1ccccc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CYP1A2 P05177 2/20 0.52
▸ ALDH1A1 P00352 2/20 0.50
▸ TSHR P16473 2/20 0.50
▸ PTPN1 P18031 1/20 0.50
▸ GRB2 P62993 1/20 0.48
▸ CES1 P23141 2/20 0.46
▸ MAPT P10636 2/20 0.46
▸ KMT2A Q03164 2/20 0.46
▸ MEN1 O00255 1/20 0.46
▸ HTT P42858 1/20 0.46
▸ RAB9A P51151 1/20 0.46
▸ CES2 O00748 1/20 0.45
▸ CYP2D6 P10635 1/20 0.43
▸ LMNA P02545 1/20 0.43
▸ CA1 P00915 1/20 0.43
▸ CA2 P00918 1/20 0.43
▸ CA5A P35218 1/20 0.43
▸ CA9 Q16790 1/20 0.43
▸ KCNN4 O15554 3/20 0.42
▸ PGK1 P00558 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30274469 0.97 CYP1A2 (0.50) CYP1A2ALDH1A1TSHRPTPN1GRB2
SCHEMBL887042 0.97 CYP1A2 (0.50) CYP1A2ALDH1A1TSHRPTPN1GRB2
SCHEMBL13199203 0.89 GRB2 (0.57) CYP1A2ALDH1A1PTPN1GRB2CES1
SCHEMBL9000492 0.86 CYP2C9 (0.61) TSHRPTPN1GRB2MAPTHTT
SCHEMBL13199336 0.85 PGK1 (0.48) CYP1A2ALDH1A1TSHRPTPN1GRB2
SCHEMBL23972372 0.84 CES2 (0.57) ALDH1A1TSHRMAPTKMT2AMEN1
SCHEMBL6666487 0.84 PTPN1 (0.50) CYP1A2ALDH1A1TSHRPTPN1CES1
SCHEMBL6967667 0.82 CES1 (0.50) CYP1A2ALDH1A1TSHRPTPN1CES1
SCHEMBL11205832 0.82 PTPN1 (0.48) CYP1A2ALDH1A1TSHRPTPN1CES1
SCHEMBL13199251 0.82 GRB2 (0.52) ALDH1A1GRB2CES1CES2CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 294 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116056706-B Biaryl derivatives useful as diacylglycerol acyltransferase 2 inhibitors and uses thereof 株式会社LG化学 2024-12-27 — — CN claimed
CN-118459453-A Preparation method of triazole antifungal drug 四川奥邦古得药业有限公司 2024-08-09 — — CN claimed
CN-116056706-A Novel biaryl derivatives useful as diacylglycerol acyltransferase 2 inhibitors and uses thereof 株式会社LG化学 2023-05-02 — — CN claimed
EP-3114715-B1 P-DOPING CROSS-LINKING OF ORGANIC HOLE TRANSPORTERS SIEMENS AG (DE) 2019-10-30 — — EP claimed
US-10040732-B2 Process for the production of biaryl compounds DSM IP ASSETS B.V. (NL) 2018-08-07 — — US claimed
EP-3169651-B1 PROCESS FOR THE PRODUCTION OF BIARYL COMPOUNDS DSM IP ASSETS BV (NL) 2018-06-20 — — EP claimed
US-20170210681-A1 PROCESS FOR THE PRODUCTION OF BIARYL COMPOUNDS DSM IP ASSETS B.V. (NL) 2017-07-27 — — US claimed
EP-3169651-A1 PROCESS FOR THE PRODUCTION OF BIARYL COMPOUNDS DSM IP Assets B.V. (NL) 2017-05-24 — — EP claimed
WO-2016008931-A1 PROCESS FOR THE PRODUCTION OF BIARYL COMPOUNDS DSM IP ASSETS B.V. (NL) 2016-01-21 — — WO claimed
EP-4727537-A2 SIGLEC LIGANDS, CONJUGATES, AND METHODS OF USE THEREOF Adaxion Therapeutics, Inc. (US) 2026-04-22 — — EP disclosed
US-20260001876-A1 Compounds and Their Use as PDE4 Activators MIRONID LIMITED (GB) 2026-01-01 — — US disclosed
US-20250388604-A1 Compounds and Their Use as PDE4 Activators MIRONID LIMITED (GB) 2025-12-25 — — US disclosed
US-12473296-B2 Perk inhibiting compounds HIBERCELL, INC. (US) 2025-11-18 — — US disclosed
EP-4572761-A1 COMPOUNDS AND THEIR USE AS PDE4 ACTIVATORS Mironid Limited (GB) 2025-06-25 — — EP disclosed
WO-1992002484-A1 PROTEIN KINASE C MODULATORS WITH ANTI-INFLAMMATORY AND ANTIVIRAL ACTIVITY ALDER RESEARCH CENTER LIMITED PARTNERSHIP (US) 1992-02-20 — — WO disclosed
EP-0432719-A1 Alkylamino- and alkylaminoalkyl diarylketones, a process for their preparation and their use as medicaments HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED (US) 1991-06-19 — — EP disclosed
US-5006563-A Alzheimer's disease HOECHST-ROUSSEL PHARMACEUTICALS INC. (US) 1991-04-09 — — US disclosed
US-4273947-A CONTACTING ACID IN LIQUID PHASE WITH HYDROGEN IN THE PRESENCE OF A RHODIUM OR IRIDIUM CATALYST ALLIED CHEMICAL CORPORATION (US) 1981-06-16 — — US disclosed
US-4118584-A 9-Deoxy-9-methylene-16-phenyl-PGF compounds THE UPJOHN COMPANY (US) 1978-10-03 — — US disclosed
US-4098805-A 9-DEOXY-9-METHYLENE-PGF-TYPE AMIDES THE UPJOHN COMPANY (US) 1978-07-04 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170210681-A1 PROCESS FOR THE PRODUCTION OF BIARYL COMPOUNDS DDT, COASY, ALDH3A1 CYP1A2 47/4885ALDH1A1 52/4885TSHR 4029/4885
US-20260001876-A1 Compounds and Their Use as PDE4 Activators PDE4A, PDE4B, PDE7A CYP1A2 511/4885ALDH1A1 1240/4885TSHR 1169/4885
US-10040732-B2 Process for the production of biaryl compounds DDT, COASY, ALDH3A1 CYP1A2 47/4885ALDH1A1 52/4885TSHR 4029/4885
US-20250388604-A1 Compounds and Their Use as PDE4 Activators PDE4A, PDE7A, PDE4B CYP1A2 380/4885ALDH1A1 989/4885TSHR 1206/4885
US-12473296-B2 Perk inhibiting compounds MAPK1, ERN1, MAP3K20 CYP1A2 2483/4885ALDH1A1 1102/4885TSHR 4533/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.